|
Study of ILX651 in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Study of ILX651 in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Study of ILX651 in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel Clinical research trials and Study of ILX651 in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Study of ILX651 in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel. Study of ILX651 in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Study of ILX651 in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel clinical trial. Human subjects frequently get the finest healthcare available for their Study of ILX651 in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of ILX651 in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel  Study of ILX651 in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel
Study of ILX651 in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel
For Condition: Hormone-Refractory Prostate Cancer
Status: Not yet recruiting
Sponsor(s): ILEX Products ,
Synopsis: This is a Phase II, non-randomized, open label study of ILX651 in patients with hormone-refractory prostate cancer previously treated with docetaxel. Approximately 40 patients will be enrolled in this study that is expected to last 24 months. All patients will be treated with ILX651 administered IV daily for 5 consecutive days every 21 days. The primary objective of this study is to determine the PSA response rate. The secondary objectives are to determine response of measurable disease, duration of response, time to PSA progression, time to treatment failure, survival, safety and tolerability, and pharmacokinetic profile of ILX651.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 19 Years/
Genders: Male
Protocol Entry Criteria: Inclusion Criteria: - (1) Patient has hormone-refractory prostate cancer (HRPC) as evidenced by PSA progression or progression of measurable disease. - (2) Patient has greater than 25% increase in 2 consecutive tests in which the first increase in PSA should occur a minimum of 1 week apart. - (3) Patients on androgen deprivation treatment and will continue on androgen deprivation treatment during study participation except for patients who are post orchiectomy. - (4) Patient has evidence of metastatic disease by positive bone scan or evidence of progressive metastatic disease by CT scan. - (5) Patient has been treated with at least 1 prior hormone therapy or is post orchiectomy. - (6) Patient has been previously treated at a minimum for an 8-week treatment period on a docetaxel-based regimen for metastatic HRPC. - (7) Patient has PSA at least 5 ng/mL or greater. - (8) Patient has testosterone less than 50 ng/dL. - (9) Patient ECOG performance status of 0 or 1. - (10) Patient has life expectancy of greater than 8 weeks. - (11) Patient meets lab values: (a) Absolute neutrophil count at least 1,500/mm^3 or greater (b) Platelet count at least 100,000/mm^3 or greater (c) Serum creatinine at least 1.5 mg/dL or less or creatinine clearance at least 60 mL/min or greater (d) Bilirubin less than 2.0 mg/dL (e) AST and ALT less or equal to 2.5 times upper limit of normal - (12) Any chemotherapy, major surgery, or irradiation must be completed at least 4 weeks prior to study drug. - (13) Patient recovered from clinically significant toxicities from prior treatment. Exclusion Criteria: - (1) Prior treatment with 2 or more prior chemotherapy regimens. - (2) Concurrent treatment with an estrogen-containing agent including diethylstilbestrol (DES). - (3) Prior flutamide (Eulexin) within past 4 weeks, prior bicalutamide (Casodex) within past 6 weeks, or prior nilutamide (Nilandron) within past 6 weeks. - (4) Prior strontium or samarium or other radioisotope therapy. - (5) Prior radiation therapy to greater than 25% of the bone marrow (e.g., no whole pelvic irradiation is allowed). - (6) Uncontrolled congestive heart failure or angina, patients with a history of myocardial infarction within 2 months of enrollment. - (7) Patients with uncontrolled hypertension. - (8) Pre-existing cardiac, pulmonary, neurologic or other disease that would preclude study participation. - (9) Documented untreated central nervous system (CNS) metastases. However, patients with treated CNS metastases that have been stable are eligible. - (10) Any significant concurrent disease or illness, or psychiatric disorders or alcohol or chemical abuse that would preclude study participation. - (11) Active secondary malignancy except non-melanoma skin cancers. - (12) Known, active infection, or known HIV positive or presence of an AIDS related illness.
Total Enrollment: 40
Location and Contact Information:
Additional Information:
Study ID Numbers: ILX651-241;
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00082134
Other Hormone-Refractory Prostate Cancer Studies:
1. Study of ILX651 in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel
2. YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
Related Studies:
Other Hormone-Refractory Prostate Cancer Clinical Trials
Other Texas Clinical Trials
Other Plano Clinical Trials
Study of ILX651 in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel
|
|
|
|
|
|
|
|
